Translational Proteomics of Normal to Benign Breast Disease
Creators: name: University Of California Office Of The President
Publisher: name: University of California Office of the President
publisherIdentifier: https://ror.org/00dmfq477
publisherIdentifierScheme: ROR
Year: 2024

description: The development of benign breast disease is an important clinical problem that is not well understood or diagnosed. It is our strong belief that understanding of the physiological changes in respect to the study of breast cell proteins (proteomics) will provide valuable progress in better diagnosing early stages of breast disease development. Proteins are the functional components of the cell that are directly responsible for disease development. To date this has been very difficult to assess however, with new innovative technology and clinical resources we can approach this field much easier now. Only through cross-multidisciplinary integration of the clinical and basic sciences can new developments be achieved with rapid application to patient care. Our approach is to address this problem examining proteomics of normal breast tissue change to benign (pre-cancer) disease. Identification of unique protein patterns associated with innovative proteomic technology will allow a better identification of those patients at increased risk developing breast cancer. The focus is on the earliest events of breast disease development. The understanding of the complexity of normal breast changes during different physiological stages of a woman during her lifetime that predispose to malignancy is advantageous. The proposal utilizes the collaborative effort of three co-PIs specialized in different aspects of breast cancer research.
 
 
 
 
 
 
 
 The central hypothesis is that benign breast disease has a unique proteomic signature pattern(s) compared to normal breast tissue. The first major question to be answered is the feasibility of developing a proteomic signature profile of normal breast tissue during different stages of women physiology. The objective is to determine changes in normal breast proteins during physiologic changes that may be risk factors to cancer development. The second question will be to determine if proteomic profile signatures of various types of benign breast disease can be used for diagnosing early stages of pre-cancerous breast disease.
 
 
 
 
 
 
 
 The primary methodology in the study is to use ProteinChip array technology to detect specific protein profiles. The study will assess normal breast and pre-cancer breast tissue biopsies from routine diagnostic surgeries to assess tissue protein profiles. This will allow assessment of normal breast tissue, benign breast tissue and early stages of pre-malignancy for unique signature proteins.
 
 
 
 
 
 
 
 This project emphasis highly translational research that applies the novel basic science field of proteomic arrays to an important breast disease problem utilizing clinical tissues. The study addresses the development of proteomic signature profiles of normal breast at different stages in an adult woman’s lifetime as a baseline for comparison to early benign breast disease. The study allows us to develop new approaches of identifying more accurately early stages of benign breast disease and prognostic factors in normal breast that identify high risk for breast disease. The development of a proteomic signature assay will also provide new approaches to assess breast tissue biopsies for more accurate diagnosis.